首页 > 最新文献

Journal of the Formosan Medical Association最新文献

英文 中文
Blood pressure targets, medication consideration and unique concerns in elderly hypertension IV: Focus on frailty, orthostatic hypotension, and resistant hypertension. 老年高血压的血压目标、用药考虑和独特关注点 IV:关注虚弱、正性低血压和抵抗性高血压。
IF 2.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-05 DOI: 10.1016/j.jfma.2024.09.022
Po-Sheng Wu, Chia-Ter Chao, Chien-Hao Hsiao, Chiu-Fen Yang, Ying-Hsiang Lee, Hung-Ju Lin, Chih-Fan Yeh, Long-Teng Lee, Kuo-Chin Huang, Meng-Chih Lee, Cheng-Kuo Huang, Yen-Hung Lin, Michael Yu-Chih Chen, Ding-Cheng Chan

Hypertension increases the risk of cardiovascular disease in the elderly. Although treating hypertension can reduce the risk of cardiovascular disease and its related mortality, it is also challenging because these patients could have frailty, orthostatic hypotension (OH) and resistant hypertension (RHTN), which makes them more susceptible to treatment-related adverse events. Identifying such patients and tailoring the choice of drugs and blood pressure targets is crucial to balance the harms and benefits. The Clinical Frailty Scale is recommended to assess elderly patients with hypertension and frailty. For very frail patients, unnecessary medications should be deprescribed to avoid adverse events. Hypertension and OH frequently co-occur in the elderly, and recognizing and managing OH is essential to prevent falls and adverse events. The management of blood pressure in elderly patients with frailty, OH, and RHTN is complex, requiring the patients, their family and caregivers to be involved in decision-making to ensure that treatment plans are well-informed and aligned with the patient's needs.

高血压会增加老年人罹患心血管疾病的风险。虽然治疗高血压可以降低心血管疾病风险及其相关死亡率,但这也是一项挑战,因为这些患者可能存在虚弱、正性低血压(OH)和抵抗性高血压(RHTN),这使他们更容易发生与治疗相关的不良事件。识别这类患者并有针对性地选择药物和血压目标对于平衡危害和益处至关重要。建议使用临床虚弱量表来评估患有高血压和虚弱的老年患者。对于非常虚弱的患者,应停用不必要的药物,以避免不良事件的发生。老年人高血压和体弱多病经常并发,识别和控制体弱多病对预防跌倒和不良事件至关重要。体弱、OH 和 RHTN 老年患者的血压管理非常复杂,需要患者、家属和护理人员参与决策,以确保治疗计划充分知情并符合患者的需求。
{"title":"Blood pressure targets, medication consideration and unique concerns in elderly hypertension IV: Focus on frailty, orthostatic hypotension, and resistant hypertension.","authors":"Po-Sheng Wu, Chia-Ter Chao, Chien-Hao Hsiao, Chiu-Fen Yang, Ying-Hsiang Lee, Hung-Ju Lin, Chih-Fan Yeh, Long-Teng Lee, Kuo-Chin Huang, Meng-Chih Lee, Cheng-Kuo Huang, Yen-Hung Lin, Michael Yu-Chih Chen, Ding-Cheng Chan","doi":"10.1016/j.jfma.2024.09.022","DOIUrl":"https://doi.org/10.1016/j.jfma.2024.09.022","url":null,"abstract":"<p><p>Hypertension increases the risk of cardiovascular disease in the elderly. Although treating hypertension can reduce the risk of cardiovascular disease and its related mortality, it is also challenging because these patients could have frailty, orthostatic hypotension (OH) and resistant hypertension (RHTN), which makes them more susceptible to treatment-related adverse events. Identifying such patients and tailoring the choice of drugs and blood pressure targets is crucial to balance the harms and benefits. The Clinical Frailty Scale is recommended to assess elderly patients with hypertension and frailty. For very frail patients, unnecessary medications should be deprescribed to avoid adverse events. Hypertension and OH frequently co-occur in the elderly, and recognizing and managing OH is essential to prevent falls and adverse events. The management of blood pressure in elderly patients with frailty, OH, and RHTN is complex, requiring the patients, their family and caregivers to be involved in decision-making to ensure that treatment plans are well-informed and aligned with the patient's needs.</p>","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ranolazine effects on exercise tolerance and angina frequency in Taiwanese stable angina: A bridging study of the CARISA randomized trial. 雷诺拉嗪对台湾稳定型心绞痛患者运动耐量和心绞痛频率的影响:CARISA 随机试验的桥接研究。
IF 2.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-05 DOI: 10.1016/j.jfma.2024.09.018
Jen-Kuang Lee, I-Chang Hsieh, Po-Hsun Huang, Yen-Wen Wu, Jung-Chung Hsu, Jen-Yuan Kuo, Po-Yuan Chang, Cheng-Hsueh Wu, Juey-Jen Hwang

Background: The effectiveness of Ranolazine on chronic angina had been proved and launched in the United States. This study aimed to determine whether add-on Ranolazine could also be effective in Taiwanese population with persisting angina symptoms despite taking conventional antianginal agents.

Methods: This is a multi-center, randomized, parallel, double-blind comparative study. The endpoint is to compare the change from the baseline of the exercise treadmill test (ETT) performing duration between add-on ranolazine and placebo at week 12.

Results: 46 patients were evaluable for the efficacy and safety endpoints. The mean change from baseline in ETT duration at week 12 was increased in the treatment and control group, and their mean difference was 20.8 s. All data in the Taiwanese population was like those in the CARISA study (24.0 s). The safety evaluation revealed that patients were tolerable to the add-on ranolazine therapy. The AE incidence for both ranolazine and placebo was 34.8%. The data were comparable to the past studies despite the limited statistical power.

Conclusion: The add-on ranolazine therapy shows the potential to raise the exercise performance and tolerance of patients with chronic angina.

背景:雷诺拉嗪对慢性心绞痛的疗效已在美国得到证实和推广。本研究旨在确定在服用常规抗心绞痛药物后仍有持续心绞痛症状的台湾人群中,加用雷诺拉嗪是否也有效:这是一项多中心、随机、平行、双盲对比研究。方法:这是一项多中心随机、平行、双盲比较研究,研究终点是比较添加雷诺拉嗪和安慰剂的患者在第12周时运动跑步机测试(ETT)持续时间与基线相比的变化:46名患者接受了疗效和安全性终点评估。第12周时,治疗组和对照组的ETT持续时间与基线相比的平均变化均有所增加,其平均差异为20.8秒。安全性评估显示,患者可以耐受加用雷诺拉嗪治疗。雷诺拉嗪和安慰剂的AE发生率均为34.8%。尽管统计能力有限,但数据与过去的研究结果相当:结论:附加雷诺拉嗪疗法具有提高慢性心绞痛患者运动能力和耐受性的潜力。
{"title":"Ranolazine effects on exercise tolerance and angina frequency in Taiwanese stable angina: A bridging study of the CARISA randomized trial.","authors":"Jen-Kuang Lee, I-Chang Hsieh, Po-Hsun Huang, Yen-Wen Wu, Jung-Chung Hsu, Jen-Yuan Kuo, Po-Yuan Chang, Cheng-Hsueh Wu, Juey-Jen Hwang","doi":"10.1016/j.jfma.2024.09.018","DOIUrl":"https://doi.org/10.1016/j.jfma.2024.09.018","url":null,"abstract":"<p><strong>Background: </strong>The effectiveness of Ranolazine on chronic angina had been proved and launched in the United States. This study aimed to determine whether add-on Ranolazine could also be effective in Taiwanese population with persisting angina symptoms despite taking conventional antianginal agents.</p><p><strong>Methods: </strong>This is a multi-center, randomized, parallel, double-blind comparative study. The endpoint is to compare the change from the baseline of the exercise treadmill test (ETT) performing duration between add-on ranolazine and placebo at week 12.</p><p><strong>Results: </strong>46 patients were evaluable for the efficacy and safety endpoints. The mean change from baseline in ETT duration at week 12 was increased in the treatment and control group, and their mean difference was 20.8 s. All data in the Taiwanese population was like those in the CARISA study (24.0 s). The safety evaluation revealed that patients were tolerable to the add-on ranolazine therapy. The AE incidence for both ranolazine and placebo was 34.8%. The data were comparable to the past studies despite the limited statistical power.</p><p><strong>Conclusion: </strong>The add-on ranolazine therapy shows the potential to raise the exercise performance and tolerance of patients with chronic angina.</p>","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to Dr. Wiwanitkit's comments on large language model applications in emergency medicine and critical care. 回复 Wiwanitkit 博士关于急诊医学和重症监护中大型语言模型应用的评论。
IF 2.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-04 DOI: 10.1016/j.jfma.2024.09.036
Haw Hwai, Yi-Ju Ho, Chih-Hung Wang, Chien-Hua Huang
{"title":"Reply to Dr. Wiwanitkit's comments on large language model applications in emergency medicine and critical care.","authors":"Haw Hwai, Yi-Ju Ho, Chih-Hung Wang, Chien-Hua Huang","doi":"10.1016/j.jfma.2024.09.036","DOIUrl":"10.1016/j.jfma.2024.09.036","url":null,"abstract":"","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinicopathological characteristics of unicentric Castleman disease: A single-center experience of 12 patients. 单中心卡斯特曼病的临床病理特征:12名患者的单中心经验
IF 2.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-02 DOI: 10.1016/j.jfma.2024.09.038
Yi-Chieh Lee, Chao-Wen Lu, Min-Shu Hsieh, Hsao-Hsun Hsu

Background: Castleman disease (CD) is an uncommon lymphoproliferative disorder with distinct pathological characteristics. Unicentric Castleman disease (UCD) presents as a single lymph node enlargement, often without significant symptoms. Complete surgical resection is the standard treatment for UCD. This study aimed to explore the clinicopathological features of UCD in a Taiwanese population.

Methods: We retrospectively identified 12 patients with UCD who had undergone surgical treatment between January 1, 2006 and June 30, 2022 at the National Taiwan University Hospital. Clinical and radiological findings were retrieved from medical records. All available pathological slides were reviewed.

Results: The patients' mean age was 38.1 years (range, 17 to 69); five (41.7%) were male, and seven (58.3%) were female. Nearly all cases of UCD were in the mediastinum, except for one case in the neck. Most patients were asymptomatic and without abnormal laboratory test results. Computed tomography revealed well-defined tumor borders, contrast enhancement, and occasional calcification. Ten patients underwent en bloc tumor resection, while the remaining two underwent partial resection. Among them, seven (58.3%) underwent video-assisted thoracoscopic surgery (VATS), and four (33.3%) underwent thoracotomy. The mean follow-up duration was 92 months. The patients who underwent total resection had no recurrence.

Conclusion: Detailed clinicopathological information on UCD in the Taiwanese population is present in our article. Both complete and partial surgery are effective for treatment. VATS may be preferred over thoracotomy due to less operative time and bleeding.

背景:卡斯特曼病(CD)是一种不常见的淋巴组织增生性疾病,具有明显的病理特征。单中心卡斯特曼病(UCD)表现为单个淋巴结肿大,通常无明显症状。完全手术切除是 UCD 的标准治疗方法。本研究旨在探讨台湾人群中 UCD 的临床病理特征:方法:我们回顾性研究了 2006 年 1 月 1 日至 2022 年 6 月 30 日期间在台湾大学医院接受手术治疗的 12 例 UCD 患者。临床和放射学检查结果均来自病历。结果:患者的平均年龄为 38.1 岁(17 至 69 岁不等);男性 5 例(41.7%),女性 7 例(58.3%)。几乎所有 UCD 病例都位于纵隔,只有一例位于颈部。大多数患者没有症状,实验室检查结果也无异常。计算机断层扫描显示肿瘤边界清晰,对比度增强,偶有钙化。十名患者接受了肿瘤全切术,其余两名患者接受了部分切除术。其中,7 人(58.3%)接受了视频辅助胸腔镜手术(VATS),4 人(33.3%)接受了开胸手术。平均随访时间为 92 个月。接受全切除术的患者没有复发:结论:本文提供了台湾 UCD 的详细临床病理资料。完全手术和部分手术都是有效的治疗方法。由于手术时间和出血量较少,VATS可能比开胸术更受欢迎。
{"title":"Clinicopathological characteristics of unicentric Castleman disease: A single-center experience of 12 patients.","authors":"Yi-Chieh Lee, Chao-Wen Lu, Min-Shu Hsieh, Hsao-Hsun Hsu","doi":"10.1016/j.jfma.2024.09.038","DOIUrl":"https://doi.org/10.1016/j.jfma.2024.09.038","url":null,"abstract":"<p><strong>Background: </strong>Castleman disease (CD) is an uncommon lymphoproliferative disorder with distinct pathological characteristics. Unicentric Castleman disease (UCD) presents as a single lymph node enlargement, often without significant symptoms. Complete surgical resection is the standard treatment for UCD. This study aimed to explore the clinicopathological features of UCD in a Taiwanese population.</p><p><strong>Methods: </strong>We retrospectively identified 12 patients with UCD who had undergone surgical treatment between January 1, 2006 and June 30, 2022 at the National Taiwan University Hospital. Clinical and radiological findings were retrieved from medical records. All available pathological slides were reviewed.</p><p><strong>Results: </strong>The patients' mean age was 38.1 years (range, 17 to 69); five (41.7%) were male, and seven (58.3%) were female. Nearly all cases of UCD were in the mediastinum, except for one case in the neck. Most patients were asymptomatic and without abnormal laboratory test results. Computed tomography revealed well-defined tumor borders, contrast enhancement, and occasional calcification. Ten patients underwent en bloc tumor resection, while the remaining two underwent partial resection. Among them, seven (58.3%) underwent video-assisted thoracoscopic surgery (VATS), and four (33.3%) underwent thoracotomy. The mean follow-up duration was 92 months. The patients who underwent total resection had no recurrence.</p><p><strong>Conclusion: </strong>Detailed clinicopathological information on UCD in the Taiwanese population is present in our article. Both complete and partial surgery are effective for treatment. VATS may be preferred over thoracotomy due to less operative time and bleeding.</p>","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142372182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insights of Fabry disease: Expert consensus approach for screening, diagnosis, and multidisciplinary management in chronic kidney disease. 法布里病的见解:慢性肾脏病筛查、诊断和多学科管理的专家共识方法。
IF 2.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-01 DOI: 10.1016/j.jfma.2024.09.033
Cheng-Jui Lin, Feng-Jung Yang, Chih-Jen Wu, Ming-Ju Wu, Mai-Szu Wu

The prevalence of Fabry disease (FD) among males with chronic kidney disease (CKD) of unknown etiology in Taiwan is 0.6%. Despite this, FD is frequently overlooked in clinical settings. To address this issue, two consensus meetings were conducted in Taiwan-one in August 2022 and another in April 2023. The first meeting established screening criteria based on age, gender, family history, cardiac involvement, and symptoms. The second meeting, with a multidisciplinary team, developed treatment recommendations. The consensus emphasizes the importance of proactive data collection in dialysis units and outpatient follow-ups to enhance FD detection and management. The screening algorithm recommends incorporating FD screening into the diagnostic process for CKD patients, regardless of age. Priority is given to patients with a family history of FD, early stroke history, or classical FD symptoms. Comprehensive screening is also advised for CKD patients without obvious classical symptoms. Screening protocols for males include measuring α-galactosidase A enzyme activity, with reduced activity leading to further tests such as lyso-Gb3 level quantification and genetic analysis. For females, the protocol involves evaluating lyso-Gb3 plasma levels and genetic testing. FD, though often underestimated, is more prevalent than recognized and necessitates a multidisciplinary approach for timely diagnosis. Enhancing awareness and adopting a comprehensive approach are essential for improving patient outcomes.

在台湾,病因不明的慢性肾脏病(CKD)男性患者中,法布里病(FD)的发病率为 0.6%。尽管如此,法布里病在临床上仍经常被忽视。为解决这一问题,台湾召开了两次共识会议,一次在 2022 年 8 月,另一次在 2023 年 4 月。第一次会议根据年龄、性别、家族史、心脏受累情况和症状制定了筛查标准。第二次会议由一个多学科团队制定治疗建议。共识强调了在透析室和门诊随访中主动收集数据以加强 FD 检测和管理的重要性。筛查算法建议将 FD 筛查纳入 CKD 患者的诊断过程中,无论患者年龄大小。优先考虑有 FD 家族史、早期中风史或典型 FD 症状的患者。对于无明显典型症状的 CKD 患者,也建议进行全面筛查。男性的筛查方案包括测量α-半乳糖苷酶A酶的活性,如果活性降低,则需要进行溶菌酶-Gb3水平定量和基因分析等进一步检查。对于女性,方案包括评估溶菌酶-Gb3 的血浆水平和基因检测。尽管 FD 经常被低估,但其发病率比公认的要高,因此需要采用多学科方法进行及时诊断。提高认识和采取综合方法对改善患者预后至关重要。
{"title":"Insights of Fabry disease: Expert consensus approach for screening, diagnosis, and multidisciplinary management in chronic kidney disease.","authors":"Cheng-Jui Lin, Feng-Jung Yang, Chih-Jen Wu, Ming-Ju Wu, Mai-Szu Wu","doi":"10.1016/j.jfma.2024.09.033","DOIUrl":"https://doi.org/10.1016/j.jfma.2024.09.033","url":null,"abstract":"<p><p>The prevalence of Fabry disease (FD) among males with chronic kidney disease (CKD) of unknown etiology in Taiwan is 0.6%. Despite this, FD is frequently overlooked in clinical settings. To address this issue, two consensus meetings were conducted in Taiwan-one in August 2022 and another in April 2023. The first meeting established screening criteria based on age, gender, family history, cardiac involvement, and symptoms. The second meeting, with a multidisciplinary team, developed treatment recommendations. The consensus emphasizes the importance of proactive data collection in dialysis units and outpatient follow-ups to enhance FD detection and management. The screening algorithm recommends incorporating FD screening into the diagnostic process for CKD patients, regardless of age. Priority is given to patients with a family history of FD, early stroke history, or classical FD symptoms. Comprehensive screening is also advised for CKD patients without obvious classical symptoms. Screening protocols for males include measuring α-galactosidase A enzyme activity, with reduced activity leading to further tests such as lyso-Gb3 level quantification and genetic analysis. For females, the protocol involves evaluating lyso-Gb3 plasma levels and genetic testing. FD, though often underestimated, is more prevalent than recognized and necessitates a multidisciplinary approach for timely diagnosis. Enhancing awareness and adopting a comprehensive approach are essential for improving patient outcomes.</p>","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term health outcomes of children born by cesarean section: A nationwide population-based retrospective cohort study in Taiwan. 剖腹产婴儿的长期健康状况:台湾一项基于全国人口的回顾性队列研究。
IF 2.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-10-01 DOI: 10.1016/j.jfma.2024.09.024
Wei Chard Chua, Yi-Lung Chen, Cheng-Fang Yen, Hsiu-Lin Chen

Background: Taiwan had high cesarean rate which exceeded the recommended threshold (15%), set by WHO. However, there have not a comprehensive study to discuss the long-term offspring consequences of cesarean section (CS). This study aimed to show whether allergy disorders, obesity and respiratory infection of children are associated with modes of delivery, using the National Health Insurance Research Database (NHIRD) of Taiwan.

Methods: This study used the maternal and child health database of NHIRD. We included the children who birth between 2004 and 2013 and inter-linked the database of the mother and children. The participants were followed until 2018/12/31. We performed a Cox proportional hazards model to identify the association of CS with respiratory tract infection, allergy disorder, and obesity diagnosed in childhood.

Results: CS significantly increased the risk of developed childhood asthma (adjusted hazard ratio [aHR] = 1.03; 95% confidence interval [CI]: 1.02-1.03), allergy rhinitis (aHR = 1.04; 95% CI: 1.04-1.05), atopic dermatitis (aHR = 1.05; 95% CI: 1.04-1.06), respiratory tract infection (aHR = 1.07; 95% CI: 1.06-1.07) and overweight (aHR = 1.29; 95% CI: 1.18-1.40) even after adjusting with confounding factor. Development of food allergy (aHR = 1.13; 95% CI: 0.87-1.47) was not associated with cesarean section.

Conclusion: This study indicated that children delivered by CS more commonly developed respiratory tract infections, asthma, allergic rhinitis, atopic dermatitis, obesity than children delivered vaginally. Among these, obesity have a stronger association with cesarean section.

背景:台湾的剖腹产率很高,超过了世界卫生组织设定的建议阈值(15%)。然而,目前还没有一项全面的研究来讨论剖腹产(CS)对后代的长期影响。本研究旨在利用台湾国民健康保险研究数据库(NHIRD),说明儿童过敏性疾病、肥胖和呼吸道感染是否与分娩方式有关:本研究使用了台湾国民健康保险研究数据库(NHIRD)的母婴健康数据库。方法:本研究使用了国家健康保险研究所的母婴健康数据库,纳入了 2004 年至 2013 年间出生的儿童,并将母亲和儿童的数据库相互连接。对参与者的随访至2018/12/31。我们采用 Cox 比例危险模型来确定 CS 与儿童期呼吸道感染、过敏性疾病和肥胖的关系:结果:CS 明显增加了儿童哮喘(调整危险比 [aHR] = 1.03;95% 置信区间 [CI]:1.02-1.03)、过敏性鼻炎(aHR = 1.04;95% 置信区间 [CI]:1.04-1.即使在对混杂因素进行调整后,过敏性鼻炎(aHR = 1.04;95% 置信区间 [CI]:1.04-1.05)、特应性皮炎(aHR = 1.05;95% 置信区间 [CI]:1.04-1.06)、呼吸道感染(aHR = 1.07;95% 置信区间 [CI]:1.06-1.07)和超重(aHR = 1.29;95% 置信区间 [CI]:1.18-1.40)的发病率仍然很高。食物过敏的发生(aHR = 1.13;95% CI:0.87-1.47)与剖腹产无关:本研究表明,与阴道分娩的婴儿相比,剖宫产的婴儿更容易患呼吸道感染、哮喘、过敏性鼻炎、特应性皮炎和肥胖症。其中,肥胖与剖腹产的关系更为密切。
{"title":"Long-term health outcomes of children born by cesarean section: A nationwide population-based retrospective cohort study in Taiwan.","authors":"Wei Chard Chua, Yi-Lung Chen, Cheng-Fang Yen, Hsiu-Lin Chen","doi":"10.1016/j.jfma.2024.09.024","DOIUrl":"https://doi.org/10.1016/j.jfma.2024.09.024","url":null,"abstract":"<p><strong>Background: </strong>Taiwan had high cesarean rate which exceeded the recommended threshold (15%), set by WHO. However, there have not a comprehensive study to discuss the long-term offspring consequences of cesarean section (CS). This study aimed to show whether allergy disorders, obesity and respiratory infection of children are associated with modes of delivery, using the National Health Insurance Research Database (NHIRD) of Taiwan.</p><p><strong>Methods: </strong>This study used the maternal and child health database of NHIRD. We included the children who birth between 2004 and 2013 and inter-linked the database of the mother and children. The participants were followed until 2018/12/31. We performed a Cox proportional hazards model to identify the association of CS with respiratory tract infection, allergy disorder, and obesity diagnosed in childhood.</p><p><strong>Results: </strong>CS significantly increased the risk of developed childhood asthma (adjusted hazard ratio [aHR] = 1.03; 95% confidence interval [CI]: 1.02-1.03), allergy rhinitis (aHR = 1.04; 95% CI: 1.04-1.05), atopic dermatitis (aHR = 1.05; 95% CI: 1.04-1.06), respiratory tract infection (aHR = 1.07; 95% CI: 1.06-1.07) and overweight (aHR = 1.29; 95% CI: 1.18-1.40) even after adjusting with confounding factor. Development of food allergy (aHR = 1.13; 95% CI: 0.87-1.47) was not associated with cesarean section.</p><p><strong>Conclusion: </strong>This study indicated that children delivered by CS more commonly developed respiratory tract infections, asthma, allergic rhinitis, atopic dermatitis, obesity than children delivered vaginally. Among these, obesity have a stronger association with cesarean section.</p>","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to comment on "The association between vitamin D consumption and gallstones in US adults: A cross-sectional study from the national health and nutrition examination survey". 对 "美国成年人维生素 D 摄入量与胆结石之间的关系:全国健康与营养状况调查横断面研究"。
IF 2.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-09-30 DOI: 10.1016/j.jfma.2024.09.030
Chuan Zhang
{"title":"Reply to comment on \"The association between vitamin D consumption and gallstones in US adults: A cross-sectional study from the national health and nutrition examination survey\".","authors":"Chuan Zhang","doi":"10.1016/j.jfma.2024.09.030","DOIUrl":"https://doi.org/10.1016/j.jfma.2024.09.030","url":null,"abstract":"","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on "Adjuvant chemotherapy for stage II and III gastric adenocarcinoma: A retrospective analysis with long-term follow-up". 就 "II期和III期胃腺癌的辅助化疗:长期随访的回顾性分析 "发表评论。
IF 2.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-09-29 DOI: 10.1016/j.jfma.2024.09.029
Feng Ma, Shouqin Hu
{"title":"Comment on \"Adjuvant chemotherapy for stage II and III gastric adenocarcinoma: A retrospective analysis with long-term follow-up\".","authors":"Feng Ma, Shouqin Hu","doi":"10.1016/j.jfma.2024.09.029","DOIUrl":"https://doi.org/10.1016/j.jfma.2024.09.029","url":null,"abstract":"","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Authorship statement 作者声明
IF 2.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-09-27 DOI: 10.1016/S0929-6646(24)00424-8
{"title":"Authorship statement","authors":"","doi":"10.1016/S0929-6646(24)00424-8","DOIUrl":"10.1016/S0929-6646(24)00424-8","url":null,"abstract":"","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142328219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guide for Authors 作者指南
IF 2.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-09-27 DOI: 10.1016/S0929-6646(24)00422-4
{"title":"Guide for Authors","authors":"","doi":"10.1016/S0929-6646(24)00422-4","DOIUrl":"10.1016/S0929-6646(24)00422-4","url":null,"abstract":"","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142328217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of the Formosan Medical Association
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1